Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Repare Therapeutics Inc (NQ: RPTX )

3.120 -0.060 (-1.89%)
Streaming Delayed Price Updated: 2:17 PM EDT, Jul 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repare Therapeutics Inc

< Previous 1 2 3 4 5 Next >
These Biotech Stocks Could Double Your Money, According To Analysts
Via Benzinga
Recap: Repare Therapeutics Q3 Earnings
Via Benzinga
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
From Repare Therapeutics Inc.
Via Business Wire
$2.8M Bet On Repare Therapeutics? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%
This small-cap biotech stock holds enormous growth potential. 
Via The Motley Fool
Analyst Expectations for Repare Therapeutics's Future
Via Benzinga
Recap: Repare Therapeutics Q1 Earnings
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Repare Therapeutics Inc.
Via Business Wire
Analyst Expectations for Repare Therapeutics's Future
Via Benzinga
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near... 
Via Benzinga
Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Repare Therapeutics Inc.
Via Business Wire
4 Analysts Have This to Say About Repare Therapeutics
Via Benzinga
Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Repare Therapeutics Inc. (NASDAQ: RPTX) Near the Top of Equities by Percentage Gain on 8/10
Via Investor Brand Network
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2023
Via Benzinga
Repare Therapeutics Releases Early Anticancer Activity From Its Monotherapy, Combination Trials
Repare Therapeutics Inc (NASDAQ: RPTX) reported initial proof of concept monotherapy data from its Phase 1 MYTHIC trial evaluating lunresertib (RP-6306) in molecularly selected  
Via Benzinga
Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights
From Repare Therapeutics Inc.
Via Business Wire
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
From Repare Therapeutics Inc.
Via Business Wire
NASDAQ: RPTX Investor Alert: Investigation over Potential Wrongdoing at Repare Therapeutics Inc.
San Diego, CA -- (SBWIRE) -- 04/28/2023 -- Certain directors of Repare Therapeutics Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.